Guardant Health (GH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Guardant Health

NasdaqGS•Healthcare•Diagnostics & Research

$159.03-3.75(-0.02%)Pre-market

Market Cap

$24.33B

P/S

20.6x

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

How this company scores

WeakMetricSide Score: 38/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (16/25); weakest: Balance Sheet & Red Flags (5/25).

Profitability11/25

Growth16/25

Balance Sheet & Red Flags5/25

Cash & Earnings Quality6/25

Strengths

Growing revenueLong cash runwayConsistent growthImproving margins

Grade capped at D

Negative equity — the balance sheet is insolvent.
Interest coverage below 1× (-87.3x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 20.6x5y range 4.1x – 35.7x

Currently above its 20-quarter median.

P/B · 36.1x5y range 12.8x – 46.3x

Currently above its 10-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $24.33B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.18B
Q. Revenue: $334.98M
TTM EBITDA: $-431.80M
TTM Op. Income: $-470.26M
Q. Op. Income: $-129.12M
TTM Net Income: $-453.44M
Q. Net Income: $-120.14M
EPS: $-0.9
Shares Out.: $132.87M

$1.18B in TTM revenue grew 42.7% YoY, reaching $334.98M last quarter. TTM EBITDA of $-431.80M and TTM operating income of $-470.26M show growth is flowing through to the bottom line. However, net income is negative at $453.44M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 65.4%
EBITDA Margin: -35.7%
Op. Margin: -38.5%
Net Margin: -35.9%

Op. margin of -38.5% is up 7.3% YoY — cost efficiency is improving. Net margin at -35.9% and gross margin of 65.4% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 20.6x
P/B Ratio: N/A

P/S of 20.6x and P/B of 0.0x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.91B
Cash: $1.05B
Long-Term Debt: $1.50B
Book Value: $-222.87M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-57.78M
TTM Free Cash Flow: $-240.72M
FCF Margin: -20.3%
FCF / Net Income: 0.5

TTM FCF of $-240.72M on $-57.78M in operating cash flow. The FCF / Net Income ratio of 0.5x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.